Guidance extended from year-end 2027 to early 2028, with operating expense reduction targets reiterated and achieved at a greater scale (now 35% year-over-year, 10% below guidance). Strategic focus ...
Bullish option flow detected in Recursion Pharmaceuticals (RXRX) with 7,493 calls trading, 2x expected, and implied vol increasing almost 4 points to 94.34%. Jan-25 6 calls and Jun-25 7 calls are the ...
Recursion Pharmaceuticals, Inc. leverages AI to accelerate drug discovery, offering both a licensing platform and an internal drug development pipeline. RXRX faces heavy competition, ongoing operating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results